Sales and Profits Advance At Eisai
Japanese pharmaceutical company Eisai achieved a 5.7% increase in sales to 253.6 billion yen ($232.4 million) in the fiscal year ended March 1996. This was driven by sales of its antigastritis agent Selbex (teprenone) and its treatment for peripheral neuropathy Methycobal (mecobalamin).
Operating profits for the year were 40.1 billion yen, up 8.4%, recurring profits amounted to 40.2 billion yen, also ahead 8.4% and net profits grew 7.1% to 18.1 billion yen. Earnings per share grew 7.1% to 70.4 yen.
In the current fiscal year, the firm expects to see growth in sales and profits, driven by steady demand for Selbex and its non-ionic contrast medium Iomeron (iomeprol).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze